Oxford Biodynamics

Oxford BioDynamics Plc, a biotechnology company, discovers and develops biomarkers for use in the pharmaceutical and biotechnology industry primarily in the United States and internationally. The company provides EpiSwitch, a proprietary technology platform for the discovery, evaluation, validation, and monitoring of epigenetic biomarkers known as chromosome conformation signatures for use in medical testing kits, disease prediction, diagnosis, and treatment. Its products include EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a validated prognostic test for predicting response to checkpoint inhibitor immunotherapy; EpiSwitch CST (Covid Severity Test), an advanced blood test for the prediction of COVID-19 severity in adults; and EpiSwitch Explorer Array Kit for high-resolution 3D genome profiling and biomarker discovery. Oxford BioDynamics Plc was incorporated in 2007 and is headquartered in Oxford, the United Kingdom.

Our mission is to enable diseases to be detected earlier, be monitored more accurately, and be better treated by partnering for biomarker enablement with global pharmaceutical companies and research organisations.

Our vision is to become the leading provider of epigenetic biomarkers for diagnosis, prognosis and stratification of diseases. We are committed to using our expertise and proprietary technologies to enable the discovery of new biomarkers and to drive the development of new diagnostic tests and medicines that will improve the lives of millions.

Oxford Biodynamics won the Queen’s Award for Enterprise in 2019 and was featured in the UK Innovation and Science Seed Fund’s ‘Innovate 2020: Game-Changing Companies’ report in 2020.